Pinned Tweet
Gracias bro ❤️🙏🏻
Mi hermano entró a la residencia cardiología y no podría estar más feliz por él 😭😭
Felicidades @GRFernandezG 🎉🎉
Guillermo Fernández retweeted
A new #JACC State-of-the-Art Review examines the interpretation of hs-cTn levels, common non-acute coronary syndrome conditions associated with troponin elevation and emerging advances that may improve diagnostic specificity. bit.ly/4sAyGKO
Guillermo Fernández retweeted
Hay algo profundamente triste en la vida que casi nunca pensamos: la mayoría de las últimas veces llegan sin avisar.
Un día tu madre te cogerá de la mano por última vez. Y probablemente ninguno de los dos será consciente de ello.
Un día saldrás de casa de tus abuelos después de una comida familiar. Te despedirás con un beso, como tantas otras veces. Sin imaginar que aquella sería la última sobremesa juntos.
Un día jugarás por última vez con ese amigo de la infancia con el que pasabas tardes enteras. No habrá una despedida. Simplemente, la vida os llevará por caminos diferentes y ninguno sabrá que aquella tarde terminó una etapa que jamás volvería.
Un día tu hijo dejará de pedirte que lo cojas en brazos. Y tú, que tantas veces estabas cansado, no recordarás cuál fue la última vez que lo levantaste del suelo.
Un día alguien te abrazará por última vez. Alguien te dirá «te quiero» por última vez. Alguien se sentará a tu lado por última vez.
Un día hablarás por última vez con esa persona que tanto te gusta. Te contará cómo le ha ido el día, os reiréis de alguna tontería y volverás a casa pensando en lo feliz que te hace alguien que ni siquiera imagina cuánto significa para ti. No sabrás que aquella fue la última vez que buscaste una excusa para verla, que escuchaste esa risa que tanto te gusta o que te ilusionaste al ver su nombre en el móvil. Y quizá nunca llegue a saber que, mientras para ella eran momentos normales de su vida, tú estabas guardando recuerdos que jamás olvidarás.
Y lo más desconcertante es que casi nunca sabemos que estamos viviendo un momento que algún día echaremos de menos.
Nos pasamos la vida esperando.
Esperando al viernes. A las vacaciones. A terminar los estudios. A conseguir un trabajo mejor. A tener más dinero. A que llegue alguien. A que las cosas cambien.
Siempre parece que la vida de verdad empezará un poco más adelante.
Y mientras esperamos, la vida está ocurriendo.
Está ocurriendo cuando tu madre te pregunta si has comido. Cuando tu abuelo te cuenta por tercera vez la misma historia. Cuando un amigo te escribe simplemente para saber cómo estás. Cuando alguien que te quiere te pide cinco minutos de tu tiempo.
Esos momentos que hoy parecen insignificantes serán, probablemente, los recuerdos por los que mañana daríamos todo lo que tenemos.
Por eso, llama a tus padres. Escucha a tus abuelos, aunque repitan sus historias. Abraza a tus amigos. Haz esa visita que llevas meses posponiendo. Perdona cuando puedas. Di «te quiero» aunque te dé vergüenza.
Y, sobre todo, no trates como una molestia aquello que algún día podrías echar terriblemente de menos.
Hay una frase del Evangelio que encierra una verdad inmensa: «Donde está tu tesoro, allí estará también tu corazón» (Mt 6,21).
Quizá nuestros verdaderos tesoros no sean las cosas que tanto nos esforzamos por conseguir, sino esas personas a las que a veces dedicamos las sobras de nuestro tiempo.
Dios nos ha regalado algo extraordinario: la posibilidad de amar hoy a quienes tenemos cerca.
No sabemos cuántos mañanas nos quedan juntos.
Pero sí sabemos que hoy todavía podemos llamar, escuchar, abrazar, acompañar y querer.
Que nunca tengamos que perder a alguien para comprender lo afortunados que éramos de tenerlo.
Y que, cuando llegue la última vez, aunque no sepamos reconocerla, al menos nos quede la paz de haber amado todo lo que pudimos.
Guillermo Fernández retweeted
Todos los días nos cruzamos con cientos de personas de las que no sabemos absolutamente nada. Un segundo. Una mirada. Una sonrisa. Y seguimos caminando.
Una mujer que acaba de perder a su madre sale a comprar el pan intentando contener las lágrimas. Todavía no sabe cómo acostumbrarse a vivir sin ella. Esa es su cruz.
Un chaval al que sus compañeros hacen la vida imposible en el colegio baja la mirada y finge que no le importa. Cada mañana le cuesta un poco más entrar por aquella puerta. Esa es su cruz.
Una joven que lleva meses buscando trabajo sonríe cuando alguien le pregunta cómo le va la vida. Responde que todo bien, aunque por dentro siente que se está quedando atrás. Esa es su cruz.
Un chico que ha visto cómo la chica de la que estaba enamorado se ha empezado a salir con uno de sus amigos. Los ve felices, sonríe cuando están delante y les desea lo mejor. Pero cuando llega a casa, llora por lo que nunca pudo ser. Esa es su cruz.
Una chica que tiene muchos conocidos, pero que se siente profundamente sola. Que mira el móvil esperando un mensaje que nunca llega. Que se acuesta temprano porque hay días en los que dormir es la única forma de dejar de pensar. Esa es su cruz.
Un hombre que lleva meses luchando contra la ansiedad. Que sale a trabajar y cumple con sus obligaciones mientras por dentro libra una batalla que nadie conoce. Esa es su cruz.
Miles de personas. Miles de historias. Miles de cruces invisibles.
Porque nadie lleva escrito en la frente cuánto está sufriendo. Nadie anuncia que anoche lloró hasta quedarse dormido. Que lleva semanas sintiéndose solo. Que echa de menos a alguien. Que está perdiendo la esperanza.
Y, sin embargo, seguimos caminando. Fingiendo que todo está bien. Sonriendo por educación. Respondiendo «bien, ¿y tú?» cuando alguien nos pregunta cómo estamos.
A veces olvidamos que detrás de cada rostro hay una historia que desconocemos. Que esa persona que hoy apenas ha hablado quizá está haciendo un esfuerzo enorme por no derrumbarse.
En el Evangelio de hoy, Jesús nos recuerda los dos mandamientos más importantes: amar a Dios sobre todas las cosas y amar al prójimo como a nosotros mismos.
Y quizá deberíamos preguntarnos más a menudo qué significa realmente amar al prójimo.
Porque amar al prójimo no consiste únicamente en hacer grandes sacrificios. También es acordarse de quien está solo. Escuchar a quien necesita desahogarse. Tener paciencia con quien está atravesando un mal momento. Preocuparse por alguien sin esperar nada a cambio.
Es comprender que Dios también nos llama a través de las personas que pone en nuestro camino.
Por eso, sé amable.
Y, sobre todo, no te olvides de ese amigo que sabes que no está pasando por su mejor momento.
Escríbele. Pregúntale cómo está. Dile que te has acordado de él. Invítale a tomar un café. Hazle saber que no está solo.
Aunque no te haya escrito primero. Aunque siempre te diga que está bien. Aunque creas que tiene a muchas otras personas con las que hablar.
Porque quizá lleva todo el día mirando el móvil esperando que alguien se acuerde de él. Quizá tu mensaje sea la única ilusión que tenga hoy. Quizá esas pocas palabras le devuelvan, aunque sea por un instante, las ganas de sonreír.
No hace falta que tengas la solución a sus problemas. A veces basta con estar. Con escuchar. Con hacer sentir a alguien que su vida importa.
Amar a Dios también significa aprender a reconocerlo en el rostro de quienes sufren. En ese amigo que se ha quedado solo. En esa persona que sonríe mientras por dentro se está rompiendo. En aquel que necesita ayuda, pero no se atreve a pedirla.
Porque no tiene sentido decir que amamos a Dios si después somos incapaces de detenernos ante el sufrimiento de nuestro hermano.
Cristo no nos pidió que amáramos solamente a quienes nos quieren, a quienes nos escriben primero o a quienes hacen nuestra vida más fácil.
Nos pidió que amáramos al prójimo. Sin condiciones.
Guillermo Fernández retweeted
👉WHEN STATINS SHOULD NOT BE MISSED
✓ Post-MI
✓ Post-stroke
✓ PAD
✓ Subclinical atherosclerosis
✓ Diabetes — almost all
✓ CKD — almost all
✓ HIV — almost all
✓ FH / LDL-C ≥190 mg/dL
👆DON’T MISS THE INDICATION
The STAREE trial tested whether atorvastatin prevents first major cardiovascular events and extends disability-free survival in adults 70 years and older without cardiovascular disease. Research findings are summarized in a new Quick Take video. nej.md/4xXoFIG
#ESCCongress
Guillermo Fernández retweeted
Hi all,
The Lp(a) HORIZON trial has released topline data and, quite shockingly, missed its primary endpoint.
In other words, lowering Lp(a) in patients with prior MI, stroke or peripheral arterial disease, who were otherwise very well treated for LDL-C, blood pressure, diabetes and other risk factors, did not reduce the primary cardiovascular endpoint.
We obviously need to see the full data before making firm conclusions, and I don’t want to speculate too much without the details.
But this is a big enough result that it is worth summarizing what we know, what we don’t know, and what this may mean for our patients after 20+ years of trying to test the “Lp(a) hypothesis.”
What we know:
1-There are hundreds if not thousands of genetic, epidemiologic and Mendelian-randomization studies showing that elevated Lp(a) is associated with MI, stroke, peripheral arterial disease and aortic stenosis. That body of evidence is very strong.
2-However, much of those data come from community-based populations, often before the era of intensive LDL-C lowering and modern secondary prevention.
3-There has been much less information about how much residual risk Lp(a) carries in someone who has already had an event and is then treated very aggressively.
4-HORIZON may have had some of the best-treated patients of any recent cardiovascular outcomes trial.
Baseline LDL-C was about 65 mg/dL, a measured LDL-C contains the cholesterol carried on Lp(a), so in reality, 15-20 points lower.
5-In patients with very high Lp(a), if you correct LDL-C for Lp(a)-cholesterol, the actual LDL-C carried by LDL particles may have been closer to 45–50 mg/dL, perhaps even lower in some patients.
6-This raises a very basic question:
Can you still demonstrate a major incremental benefit from lowering another apoB-containing particle when the underlying LDL burden has already been driven this low?
What we don’t know:
1-What was the actual corrected LDL-C in these patients? I think it would be extremely informative to directly measure Lp(a)-C and calculate corrected LDL-C. This may tell us a lot about the biological setting in which pelacarsen was being tested.
2- What was the OxPL status? Our prior work has suggested that much of the pro-inflammatory biology associated with Lp(a) is related to its enrichment in oxidized phospholipids. Did OxPL fall? Did patients with higher OxPL derive more benefit? Was Lp(a) concentration actually identifying the patients with the most pathogenic particles?
3- Did we measure the right component of Lp(a) for trial inclusion? We generally measure molar particle concentration. But is molar concentration itself the main driver of risk, or is it partly a surrogate for what the particle carries? Cholesterol? Triglycerides? Oxidized phospholipids? Other proteins? Could two patients with the same Lp(a) concentration have very different Lp(a)-mediated risk? I think this question deserves much more attention.
3- Were the genetic data telling us exactly what we thought they were telling us? The genetic data are extremely compelling, but genetics reflect lifelong exposure. A clinical trial treats patients late in life, often after decades of arterial injury and after an event has already occurred. Those are not necessarily the same experiment. Could there also be some unrecognized biology linked to the LPA locus that we have not completely accounted for? That possibility should at least be considered.
3- Does very low LDL-C modify the Lp(a) risk relationship? Maybe Lp(a) is particularly important when LDL-C is higher, but its contribution becomes smaller once LDL-C is driven to very low levels. Again, we need the data.
4- Does aspirin or other antiplatelet therapy reduce part of the risk associated with Lp(a)? Lp(a) has potentially important prothrombotic effects. Almost everyone in a trial like HORIZON is receiving contemporary antiplatelet therapy. Could that blunt one component of the risk associated with Lp(a)?
5- Why are these patients still having events? This may be one of the most interesting questions of all. These are patients with LDL-C around 65 mg/dL, and perhaps corrected LDL-C substantially lower, yet cardiovascular events continue to occur. What is driving that residual risk? Inflammation? Thrombosis? Plaque burden that is already too advanced? Other lipoprotein characteristics? Something we are not measuring?
6- Do we need to re-examine some basic assumptions about atherosclerosis? We have spent decades focusing heavily on the quantity of circulating lipoproteins. But perhaps lipoproteins are relatively benign until they undergo biological modification in the artery wall. Oxidation may be one of those key modifications. For some patients, the answer may be to remove more particles from the circulation. For others, perhaps the better approach is to prevent their oxidation or block the downstream biological effects of oxidized lipids. The recent difficulties with anti-inflammatory approaches, including IL-6 inhibition, make these mechanistic questions even more interesting.
7- Was there something specific about pelacarsen, the degree or timing of Lp(a) lowering, advanced disease, trial duration, background therapy or patient selection that mitigated a potential benefit? We simply don’t know yet. That is why the detailed results will be so important.
What does this mean for patients today?
If you have already had an MI, stroke or PAD, the immediate lesson is very clear:
1- Get all of your established risk factors treated aggressively.
2- Get LDL-C/apoB very low.
3- Control blood pressure.
4- Control diabetes.
5- Don’t smoke.
6- Use appropriate antiplatelet and other guideline-directed therapies.
HORIZON shows us what modern secondary prevention should look like.
If you have elevated Lp(a) but have never had an event, the genetic and epidemiologic data still suggest increased lifetime risk.
Until the other 4 outcome trials read out, I would continue to treat every modifiable risk factor aggressively.
We should wait for those trials before drawing broad conclusions about the entire field.
I think the story of Lp(a) therapy is beginning, not ending.
We also need to show tremendous respect and gratitude to the patients who participated in HORIZON and to the investigators and companies that invested enormous resources to actually test the Lp(a) hypothesis, to the ultimate benefit to peole with elevated Lp(a) to best guide how to manage risk.
More to come as we go forward.
Guillermo Fernández retweeted
🚨 ESC 2026 | HOT LINE TRIALS
📊 16 ensayos en una tabla: qué se estudió, qué cambió la práctica y qué quedó en negativo o con matices.
🟢 Positivo | 🟡 Mixto | 🔴 Negativo
#ESCCongress #ESC2026
🤖 Made with AI
Guillermo Fernández retweeted
🚨 10 striking conclusions from ESC 2026
1. HFmrEF is essentially gone.
ESC now defines HFrEF as LVEF <50% and HFpEF as ≥50%.
2. MRAs have broken the EF barrier.
Mineralocorticoid receptor antagonists now have a Class I recommendation in chronic HF irrespective of LVEF. Semaglutide/tirzepatide receive Class IIa recommendations for HFpEF with obesity.
3. SINGLE-AF: anticoagulation may start earlier than we thought.
In AF patients at intermediate stroke risk, DOAC therapy reduced adverse clinical outcomes by 69% versus no anticoagulation.
4. Severe TR is no longer just “give diuretics and watch.”
TRIC-I-HF: transcatheter tricuspid repair reduced HF hospitalisation and all-cause mortality compared with medical therapy alone.
5. Unexplained syncope deserves early prolonged ECG monitoring.
ASPIRED: immediate 14-day monitoring did not prevent recurrent syncope, but substantially improved arrhythmia diagnosis/treatment and was associated with lower mortality.
6. Intermediate–high-risk PE may be entering the catheter era.
PRAGUE-26: catheter-directed thrombolysis improved short-term clinical outcomes versus anticoagulation alone, without an obvious major bleeding penalty.
7. Cardiac arrest + no STEMI ≠ automatic immediate cath lab.
DISCO: immediate angiography after OHCA without ST elevation did not improve 30-day survival.
8. Being ≥70 is not a reason to abandon primary-prevention statins.
STAREE: atorvastatin reduced major cardiovascular events by about 30% in older adults without known CVD, although disability-free survival was unchanged.
9. AF ablation has a surprisingly large placebo component for symptoms.
PVI-SHAM-AF: ablation reduced AF recurrence, yet improvement in AF-related quality of life was not significantly greater than sham treatment.
10. Even the definition of MI has changed.
The 5th Universal Definition of MI replaces the traditional numbered framework with primary MI, secondary MI and procedure-related MI, while incorporating sex-specific troponin thresholds and greater use of imaging.
🔥 The one-line ESC 2026 message:
Treat HF across the EF spectrum, anticoagulate selected AF patients earlier, intervene on TR, monitor syncope sooner—and stop rushing every post-arrest patient without STEMI to the cath lab.
Guillermo Fernández retweeted
The Consultant Cardiologist after prescribing SGLT2i to all his Clinic Patients after the ESC cardiology Congress 2026.
Guillermo Fernández retweeted
☝️Atherosclerosis starts earlier than we think
👉New data from the REACT study, published in NEJM, provide a striking picture of silent atherosclerosis across adult life:
1️⃣ 16,808 adults, aged 18–70 years, without known ASCVD.
2️⃣ Multimodal imaging included 3D carotid and femoral ultrasound plus coronary CT angiography.
3️⃣ Silent atherosclerosis was present in 57.1% of participants.
4️⃣ Even at 18–29 years, plaque was already present in 8.7% of men and 6.7% of women.
5️⃣ By age 30–39, prevalence reached 34.6% in men and 21.3% in women.
6️⃣Atherosclerosis appeared 5–10 years earlier in men, while women showed a later but steeper rise in midlife.
7️⃣ In younger adults, disease was usually peripheral and single-territory, especially carotid; with age, plaque burden increased exponentially and disease became increasingly multiterritorial.
8️⃣ ☝️Importantly, CAC = 0 did not exclude coronary plaque: among 30–39-year-olds with coronary atherosclerosis, ~42% of men and ~48% of women had zero coronary calcium
9️⃣ SCORE2 showed major discordance with actual disease burden: high SCORE2 had only 1.9% sensitivity for silent atherosclerosis.
☝️Key message: low short-term cardiovascular risk does not mean absence of atherosclerosis.
👉Risk scores estimate events. Imaging detects disease. REACT reminds us that prevention should begin long before cardiovascular risk becomes “high.”
🔗 nejm.org/doi/full/10.1056/NE…
@society_eas
Guillermo Fernández retweeted
🫀 LLEGÓ LA 5ta DEFINICIÓN UNIVERSAL DEL INFARTO DE MIOCARDIO ESC/ACC/AHA/WHF, 2026
@escardio @ACCinTouch @American_Heart @worldheartfed #ESCCongress #STEMI
Abro hilo 🧵 con puntos claves
academic.oup.com/eurheartj/a…
Guillermo Fernández retweeted
🗣️ "Tengo dos hermanos menores y ellos también querían jugar al tenis, pero no pudieron recibir el mismo apoyo que yo. Mis padres se sentían mal por eso. Por eso me hice una promesa: retribuirles a ellos y a mis hermanos para que tengan la mejor vida posible."
— Novak Djokovic
Guillermo Fernández retweeted
Hozier, Pedro Pascal, Mark Ruffalo expresaron “gran preocupación” cuando Estados Unidos se llevó al tirano, pero con un terremoto masivo no dicen nada.
Es como si no les importara la gente en realidad si no temas que se alineen con su ideología política.
Guillermo Fernández retweeted
🙌 Our last manuscript is out.
👉“Safety of Very Low LDL-Cholesterol:
Ten Common Concerns, Misconceptions, and Evidence-Based Clarifications”
📍Very low LDL-C levels continue to generate debate, fear, and misinformation in clinical practice.
📍In this review, we critically examined 10 of the most frequent concerns related to intensive LDL-C lowering:
— Cognitive decline
— Hemorrhagic stroke
— Cancer
— Cataracts
— Hormonal dysfunction
— Diabetes risk
— Muscle symptoms
— Older adults
— Sex differences
— Overall cardiovascular benefit
📍The key message is clear:
RCTs, meta-analyses, and genetic evidence consistently support the safety profile of very low achieved LDL-C levels in appropriately selected high-risk patients.
📍Some adverse effects are real — particularly statin-associated dysglycemia and muscle symptoms — but their absolute risk is generally modest compared with the magnitude of ASCVD risk reduction.
📍Therapeutic inertia and misinformation remain major barriers in preventive cardiology. Evidence-based communication matters.
📍Lower LDL-C. Earlier. Longer. Safer than many still believe.
☝️Proud to collaborate with outstanding colleagues from Latin America, Europe, and beyond in this international effort.
🔗 doi.org/10.1016/j.atheroscle…
@society_eas
@ATHjournal
Guillermo Fernández retweeted
Thyroid dysfunction and cardiovascular disease. A State-of-the-Art review in #EHJ
👉 ow.ly/I7Jx50YQTxc
@RoccoMontone @ehj_ed
Guillermo Fernández retweeted
Guiando TRRC en descongestión por Ecocardiografia de Cuidados Críticos
Relación E/A: 2.5
Relación E/é: 32.6
Presión capilar pulmonar estimada por Nagueh: 32 mmHg
Porta: 62%
LUS score : 25
#UTIC #TRRC #ECOCRITICO
Guillermo Fernández retweeted
🫀 Did you know where the recommendation to place the pulsed wave Doppler sample volume 0.5–1 cm from the aortic valve to measure LVOT VTI comes from?
The answer is more interesting than it seems. It doesn’t come from a single study or an experiment designed for that purpose. It comes from a historical chain spanning nearly 40 years:
🔬 1982–1984 — The physical foundation
Pasipoularides and Murgo demonstrated using invasive catheters and mathematical models that in aortic stenosis there is a real zone of flow acceleration in the LVOT, just proximal to the valve, without any second anatomic obstruction. Pure hemodynamics — no Doppler yet.
👉 Bird et al. Circulation 1982 → doi.org/10.1161/01.CIR.66.4.…
👉 Pasipoularides et al. Am J Physiol 1984 → doi.org/10.1152/ajpheart.198…
📐 1984 — The apical 5-chamber view
Lewis, Kuo and Quinones were the first to validate cardiac output measurement using pulsed wave Doppler from the cardiac apex. They described placing the sample volume “immediately proximal to the aortic valve leaflets” — but without specifying any distance in centimeters.
👉 Lewis et al. Circulation 1984 → doi.org/10.1161/01.CIR.70.3.…
📏 1985 — The first numerical distance
Skjaerpe, Hegrenaes and Hatle (the Norwegian group) were the first to quantify this in Doppler: they empirically observed that flow acceleration began 0.5 to 1.5 cm proximal to the valve, and placed the sample volume just proximal to that zone. They directly cited Pasipoularides as supporting evidence. This was the first time a numerical distance appeared in the technique.
👉 Skjaerpe et al. Circulation 1985 → doi.org/10.1161/01.CIR.72.4.…
📊 1986–1988 — Practical consolidation
Otto et al. used ~1.0 cm. Oh, Tajik and the Mayo Clinic group explicitly established the range of 0.5 to 1.0 cm in 100 patients, justifying it as necessary to avoid the subvalvular acceleration zone. This is the figure we all recognize today.
👉 Otto et al. JACC 1986 → doi.org/10.1016/S0735-1097(8…
👉 Zoghbi et al. Circulation 1986 → doi.org/10.1161/01.CIR.73.3.…
👉 Oh et al. JACC 1988 → doi.org/10.1016/0735-1097(88…
📋 2002 — It becomes “official”
Quinones, Otto, Zoghbi and colleagues codified it in the ASE guidelines as “~5 mm proximal to the aortic valve”… but without citing any specific study to support it. It had already become expert consensus.
👉 Quiñones et al. JASE 2002 → doi.org/10.1067/mje.2002.120…
⚔️ 2017 — The debate reopens
Baumgartner et al. (EACVI/ASE) maintained the 0.5–1 cm recommendation. However, Hahn and Pibarot responded with a critical letter pointing out that the original articles from the 1980s measured at the aortic annulus, not 0.5–1 cm below it, and that moving away from the annulus introduces errors due to the elliptical and irregular shape of the subannular LVOT.
👉 Baumgartner et al. Eur Heart J Cardiovasc Imaging 2017 → doi.org/10.1093/ehjci/jew335
👉 Hahn & Pibarot. JASE 2017 → doi.org/10.1016/j.echo.2017.…
💡 Bottom line:
The 0.5–1 cm figure was never experimentally validated as the optimal distance. It emerged from empirical observations in the 1980s aimed at avoiding a flow acceleration zone that had been demonstrated with invasive catheters. It was adopted through accumulated clinical practice and later elevated to a formal recommendation by consensus. The debate over whether to measure at the annulus or 0.5–1 cm below it remains open to this day.
One of those recommendations we all follow but few know where it actually came from 🙂
Dr Benigno Valderrábano Salas
@MDBeni
@JaeKOh2 @ottoecho @WilliamZoghbi @ASE360 @EACVIPresident @NephroP @iamritu @PPibarot @hahn_rt @MAecocardio @SISIACOficial @SONECOM_AC @VazyurVasquez @Cardiotweets83 @HEARTof_echo @echobasics




































